Annexins as disease modifiers

Histology and Histopathology

Volumn 25, Issue 4, 2010, Pages 527-532

  Fatimathas, Lux ^a   Moss, Stephen E ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Calpactin; Cancer; Diabetes; Lipocortin; Synexin

Indexed keywords

ANNEXIN;

ANIMAL; ANTIPHOSPHOLIPID SYNDROME; DIABETES MELLITUS; DISEASE COURSE; DISEASE MODEL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INFLAMMATION; MALE; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY; REVIEW; TUMOR CELL LINE;

ANIMALS; ANNEXINS; ANTIPHOSPHOLIPID SYNDROME; CELL LINE, TUMOR; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; MALE; NEOPLASMS;

EUKARYOTA;

EID: 77950191136     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Ahn S.H., Sawada H., Ro J.Y. and Nicolson G.L. (1997). Differential expression of annexin I in human mammary ductal epithelial cells in normal and benign and malignant breast tissues. Clin. Exp. Metastasis 15, 151-156.
2. Babbin B.A., Parkos C.A., Mandell K.J., Winfree L.M., Laur O., Ivanov A.I. and Nusrat A. (2007). Annexin 2 regulates intestinal epithelial cell spreading and wound closure through Rho-related signaling. Am. J. Pathol. 170, 951-966.
3. Bhargava R., Gerald W.L., Li A.R., Pan Q., Lal P., Ladanyi M. and Chen B. (2005). EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod. Pathol. 18, 1027-1033.
4. Buday L., Farkas G. and Farago A. (1989). The dominant substrate of protein kinase C in the extracts of pig granulocytes is a 38 kDa Ca2+/membrane binding protein. Acta Biochim. Biophys. Hung. 24, 101-106.
5. Cesarman-Maus G., Rios-Luna N.P., Deora A.B., Huang B., Villa R., Cravioto M.C., Arcon-Segovia D., Sanchez-Guerrero J. and Hajjar K.A. (2006). Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. Blood 107, 4375-4382.
6. Chatterjee B.E., Yona S., Rosignoli G., Young R.E., Nourshargh S., Flower R.J. and Perretti M. (2005). Annexin 1-deficient neutrophils exhibit enhanced transmigration in vivo and increased responsiveness in vitro. J. Leukoc. Biol. 78, 639-646.
7. Chetcuti A., Margan S.H., Russell P., Mann S., Millar D.S., Clark S.J., Rogers J., Handelsman D.J. and Dong Q. (2001). Loss of annexin II heavy and light chains in prostate cancer and its precursors. Cancer Res. 61, 6331-6334.
8. Chuthapisith S., Bean B.E., Cowley G., Eremin J.M., Samphao S., Layfield R., Kerr, I.D., Wiseman J., El-Sheemy M., Sreenivasan T. and Eremin O. (2009). Annexins in human breast cancer: Possible predictors of pathological response to neoadjuvant chemotherapy. Eur. J. Cancer. 45, 1274-1281.
9. Creutz C.E., Pazoles C.J. and Pollard H.B. (1978). Identification and purification of an adrenal medullary protein (synexin) that causes calcium-dependent aggregation of isolated chromaffin granules. J. Biol. Chem. 253, 2858-2866.
10. Crompton M.R., Owens R.J., Totty N.F., Moss S.E., Waterfield M.D. and Crumpton M.J. (1988). Primary structure of the human, membraneassociated Ca2+-binding protein p68 a novel member of a protein family. EMBO J. 7, 21-27.
11. D'Acquisto F., Paschalidis N., Sampaio A.L., Merghani A., Flower R.J. and Perretti M. (2007). Impaired T cell activation and increased Th2 lineage commitment in Annexin-1-deficient T cells. Eur. J. Immunol. 37, 3131-3142.
12. Davis A.J., Butt J.T., Walker J.H., Moss S.E. and Gawler D.J. (1996). The Ca2+-dependent lipid binding domain of P120GAP mediates protein-protein interactions with Ca2+-dependent membrane-binding proteins. Evidence for a direct interaction between annexin VI and P120GAP. J. Biol. Chem. 271, 24333-24336.
13. Duncan R., Carpenter B., Main L.C., Telfer C. and Murray G.I. (2008). Characterisation and protein expression profiling of annexins in colorectal cancer. Br. J. Cancer 98, 426-433.
14. Falsey R.R., Marron M.T., Gunaherath G.M., Shirahatti N., Mahadevan D., Gunatilaka A.A. and Whitesell L. (2006). Actin microfilament aggregation induced by withaferin A is mediated by annexin II. Nat. Chem. Biol. 2, 33-38.
15. Gavins F.N., Yona S., Kamal A.M., Flower R.J. and Perretti M. (2003). Leukocyte antiadhesive actions of annexin 1. Blood 101, 4140-4147.
16. Ghitescu L.D., Gugliucci A. and Dumas F. (2001). Actin and annexins I and II are among the main endothelial plasmalemma-associated proteins forming early glucose adducts in experimental diabetes. Diabetes 50, 1666-1674.
17. Glenney J. (1986). Two related but distinct forms of the Mr 36,000 tyrosine kinase substrate (calpactin) that interact with phospholipids and actin in a Ca2+-dependent manner. Proc. Natl. Acad. Sci. USA 83, 4258-4262.
18. Grewal T., Evans R., Rentero C., Tebar F., Cubells L., de Diego. I, Kirchhoff M.F., Hughes W.E., Heeren J., Rye K.A., Rinninger F., Daly R.J., Pol A. and Enrich C. (2005). Annexin A6 stimulates the membrane recruitment of p120GAP to modulate Ras and Raf-1 activity. Oncogene 24, 5809-5820.
19. Gugliucci A. and Ghitescu L. (2002). Is diabetic hypercoagulability an acquired annexinopathy? Glycation of annexin II as a putative mechanism for impaired fibrinolysis in diabetic patients. Med. Hypotheses 59, 247-251.
20. Hajjar K.A., Jacovina A.T. and Chacko D.J. (1994). An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J. Biol. Chem. 269, 21191-21197.
21. Hastie C., Masters J.R., Moss S.E. and Naaby-Hansen S. (2008). Interferon-gamma reduces cell surface expression of annexin 2 and suppresses the invasive capacity of prostate cancer cells. J. Biol. Chem. 283, 12595-12603.
22. Hayes M.J., Shao D., Bailly M. and Moss S.E. (2006). Regulation of actin dynamics by annexin 2. EMBO J. 25, 1816-1826.
23. Hofmann S., Franke A., Fischer A., Jacobs G., Nothnagel M., Gaede K.I., Schurmann M., Muller-Quernheim J., Krawczak M., Rosenstiel P. and Schreiber S. (2008). Genome-wide association study identifies ANXA11 as a new susceptibility locus for sarcoidosis. Nat Genet. 40, 1103-1106.
24. Ishii H., Hiraoka M., Tanaka A., Shimokado K. and Yoshida M. (2007). Recombinant annexin-2 inhibits the progress of diabetic nephropathy in a diabetic mouse model via recovery of hypercoagulability. Thromb. Haemost. 97, 124-128.
25. Ishii H., Yoshida M., Hiraoka M., Hajjar K.A., Tanaka A., Yasukochi Y. and Numano F. (2001). Recombinant annexin II modulates impaired fibrinolytic activity in vitro and in rat carotid artery. Circ. Res. 89, 1240-1245.
26. Jagerbrink T., Lexander H., Palmberg C., Shafqat, J., Sharoyko V., Berggren P.O., Efendic S., Zaitsev S. and Jornvall H. (2007). Differential protein expression in pancreatic islets after treatment with an imidazoline compound. Cell Mol. Life Sci. 64, 1310-1316.
27. Jorgensen C.S., Levantino G., Houen G., Jacobsen S., Halberg P., Ullman S., Khamashta M.A., Asmussen K., Oxholm P., Jorgensen M.K., van Venrooij W.J. and Wiik A. (2000). Determination of autoantibodies to annexin XI in systemic autoimmune diseases. Lupus 9, 515-520.
28. Kang J.S., Calvo B.F., Maygarden S.J., Caskey L.S., Mohler J.L. and Ornstein D.K. (2002). Dysregulation of annexin I protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer. Clin. Cancer Res. 8, 117-123.
29. Kollermann J., Schlomm T., Bang H., Schwall G.P., von Eichel-Streiber C., Simon R., Schostak M., Huland H., Berg W., Sauter G., Klocker H. and Schrattenholz A. (2008). Expression and prognostic relevance of annexin A3 in prostate cancer. Eur. Urol. 54, 1314-1323.
30. Lei H., Romeo G. and Kazlauskas A. (2004). Heat shock protein 90alpha-dependent translocation of annexin II to the surface of endothelial cells modulates plasmin activity in the diabetic rat aorta. Circ. Res. 94, 902-909.
31. Lim L.H., Solito E., Russo-Marie F., Flower R.J. and Perretti M. (1998). Promoting detachment of neutrophils adherent to murine postcapillary venules to control inflammation: effect of lipocortin 1. Proc. Natl. Acad. Sci. USA 95, 14535-14539.
32. Ling Q., Jacovina A.T., Deora A., Febbraio M., Simantov R., Silverstein R.L., Hempstead B., Mark W.H. and Hajjar K.A. (2004). Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J. Clin. Invest 113, 38-48.
33. Lopez-Pedrera C., Cuadrado M.J., Herandez V., Buendia P., Aguirre M.A., Barbarroja N., Torres L.A., Villalba J.M., Velasco F. and Khamashta M. (2008). Proteomic analysis in monocytes of antiphospholipid syndrome patients: Deregulation of proteins related to the development of thrombosis. Arthritis Rheum. 58, 2835-2844.
34. Lu Q.Y., Jin Y.S., Zhang Z.F., Le A.D., Heber D., Li F.P., Dubinett S.M. and Rao J.Y. (2007). Green tea induces annexin-I expression in human lung adenocarcinoma A549 cells: involvement of annexin-I in actin remodeling. Lab. Invest. 87, 456-465.
35. Ma K., Simantov R., Zhang J.C., Silverstein R., Hajjar K.A. and McCrae K.R. (2000). High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II. J. Biol. Chem. 275, 15541-15548.
36. Misaki Y., Pruijn G.J., van der Kemp A.W. and van Venrooij W.J. (1994). The 56K autoantigen is identical to human annexin XI. J. Biol. Chem. 269, 4240-4246.
37. Ohnishi M., Tokuda M., Masaki T., Fujimura T., Tai Y., Itano T., Matsui H., Ishida T., Konishi R. and Takahara J. (1995). Involvement of annexin-I in glucose-induced insulin secretion in rat pancreatic islets. Endocrinology 136, 2421-2426.
38. Perretti M. and D'Acquisto F. (2009). Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat. Rev. Immunol. 9, 62-70.
39. Perretti M., Croxtall J.D., Wheller S.K., Goulding N.J., Hannon R. and Flower R.J. (1996). Mobilizing lipocortin 1 in adherent human leukocytes downregulates their transmigration. Nat. Med. 2, 1259-1262.
40. Rand J., Eerden P.V., Wu X.X. and Chazotte C. (2005). Defective annexin A5 crystallization: a mechanism for pregnancy losses in the antiphospholipid syndrome. Thromb. Res. 115 (Suppl 1), 77-81.
41. Rand J.H., Wu X.X., Quinn A.S. and Taatjes D.J. (2008). Resistance to annexin A5 anticoagulant activity: a thrombogenic mechanism for the antiphospholipid syndrome. Lupus 17, 922-930.
42. Rescher U., Ludwig C., Konietzko V., Kharitonenkov A. and Gerke V. (2008). Tyrosine phosphorylation of annexin A2 regulates Rhomediated actin rearrangement and cell adhesion. J. Cell Sci. 121, 2177-2185.
43. Salle V., Maziere J.C., Smail A., Cevallos R., Maziere C., Fuentes V., Tramier B., Makdassi R., Choukroun G., Vittecoq O., Goeb V. and Ducroix J.P. (2008). Anti-annexin II antibodies in systemic autoimmune diseases and antiphospholipid syndrome. J. Clin. Immunol. 28, 291-297.
44. Sharma M.R., Koltowski L., Ownbey R.T., Tuszynski G.P. and Sharma M.C. (2006). Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp. Mol. Pathol. 81, 146-156.
45. Shen, D., Nooraie F., Elshimali Y., Lonsberry V., He J., Bose S., Chia D., Seligson D., Chang H.R. and Goodglick L. (2006). Decreased expression of annexin A1 is correlated with breast cancer development and progression as determined by a tissue microarray analysis. Hum. Pathol. 37, 1583-1591.
46. Sorice M., Longo A., Capozzi A., Garofalo T., Misasi R., Alessandri C., Conti F., Buttari B., Rigano R., Ortona E. and Valesini G. (2007). Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum. 56, 2687-2697.
47. Srivastava M., Bubendorf L., Srikantan V., Fossom L., Nolan L., Glasman M., Leighton X., Fehrle W., Pittaluga S., Raffeld M., Koivisto P., Willi N., Gasser T.C., Kononen J., Sauter G., Kallioniemi O.P., Srivastava S. and Pollard H.B. (2001). ANX7, a candidate tumor suppressor gene for prostate cancer. Proc. Natl. Acad. Sci. USA 98, 4575-4580.
48. Srivastava M., Torosyan Y., Raffeld M., Eidelman O., Pollard H.B. and Bubendorf L. (2007). ANXA7 expression represents hormonerelevant tumor suppression in different cancers. Int. J. Cancer 121, 2628-2636.
49. van de Graaf S.F., Hoenderop J.G., Gkika D., Lamers D., Prenen J., Rescher U., Gerke V., Staub O., Nilius B. and Bindels R.J. (2003). Functional expression of the epithelial Ca(2+) channels (TRPV5 and TRPV6) requires association of the S100A10-annexin 2 complex. EMBO J. 22, 1478-1487.
50. Vila de Muga S., Timpson P., Cubells L., Evans R., Hayes T.E., Rentero C., Hegemann A., Reverter M., Leschner J., Pol A., Tebar F., Daly R.J., Enrich C. and Grewal T. (2009). Annexin A6 inhibits Ras signalling in breast cancer cells. Oncogene 28, 363-377.
51. White I.J., Bailey L.M., Aghakhani M.R., Moss S.E. and Futter C.E. (2006). EGF stimulates annexin 1-dependent inward vesiculation in a multivesicular endosome subpopulation. EMBO J. 25, 1-12.
52. Xiao G.S., Jin Y.S., Lu Q.Y., Zhang Z.F., Belldegrun A., Figlin R., Pantuck A., Yen Y., Li F. and Rao J. (2007). Annexin-I as a potential target for green tea extract induced actin remodeling. Int. J. Cancer 120, 111-120.
53. Xin W., Rhodes D.R., Ingold C., Chinnaiyan A.M. and Rubin M.A. (2003). Dysregulation of the annexin family protein family is associated with prostate cancer progression. Am. J. Pathol. 162, 255-261.
54. Yokota Y., Bargagna-Mohan P., Ravindranath P.P., Kim K.B. and Mohan R. (2006). Development of withaferin A analogs as probes of angiogenesis. Bioorg. Med. Chem. Lett. 16, 2603-2607.
55. Zhang J. and McCrae K.R. (2005). Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies. Blood 105, 1964-1969.